Greg Gould

Greg Gould, CPA, is Chief Financial Officer, Treasurer and Secretary at Aytu BioScience, Inc. Mr. Gould has held senior management positions in the life sciences industry for over 20 years. Prior to the formation of Aytu BioScience, Inc., he provided financial and operational consulting services to the biotech industry through his consulting company, Gould LLC, from April 2012 until June 2014. Mr. Gould was Chief Financial Officer, Treasurer and Secretary of SeraCare from November 2006 until the company was sold to Linden Capital Partners in April 2012. During the period from July 2011 until April 2012 Mr. Gould also served as the Interim President and Chief Executive Officer of SeraCare Life Sciences. Mr. Gould has held several other executive positions at publicly traded life sciences companies including the Chief Financial Officer role at Atrix Laboratories, Inc., an emerging specialty pharmaceutical company focused on advanced drug delivery. During Mr. Gould’s tenure there, he was instrumental in the negotiation and sale of the company to QLT, Inc. for over $855M. He also played a critical role in the management of several licensing agreements including the global licensing agreement with Sanofi-Synthelabo of the ELIGARD products. Mr. Gould was the Chief Financial Officer at Colorado MEDtech, Inc., a publicly traded medical device design and manufacturing company where he negotiated the transaction to sell the company to KRG Capital Partners. Mr. Gould began his career as an auditor with Arthur Andersen, LLP. He currently serves on the board of directors of CytoDyn Inc., a publicly traded drug development company pursuing antiviral agents for the treatment of HIV. Mr. Gould graduated from the University of Colorado with a B.S. in business administration and is a Certified Public Accountant. Mr. Gould also serves as the Chief Financial Officer, Treasurer and Secretary of publicly traded Ampio Pharmaceuticals.